CR Bard Inc. hopes to be first on the U.S. market with a drug-coated balloon through its purchase of privately held Lutonix Inc. for up to $325 million under a deal announced Dec. 20.
Lutonix’ Moxy paclitaxel-coated percutaneous transluminal angioplasty balloon is being evaluated in a pivotal U.S